OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer reporting on Form 20-F, furnished this Form 6-K on February 14, 2023. The filing announces an allotment of ordinary shares and total voting rights. The underlying announcement is referenced as Exhibit 99.1, but its substantive text is not included in the provided filing content.
Financial Metrics and Capitalization
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: the filing text does not provide clear values.
- Ordinary shares were allotted, but the number of shares issued, issue price, proceeds, resulting share capital, and total voting rights are not provided in the available text.
Material Changes Versus the Prior Comparable Period
The filing indicates a change in the company’s ordinary share count and voting rights resulting from an allotment. The filing text does not provide sufficient detail to quantify the change or compare it with a prior period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risks, contingencies, or unusual operating items are disclosed in the provided filing text. The filing is administrative in nature and furnishes the referenced announcement rather than presenting financial results.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the number and class of shares allotted.
- Verify the issue price, gross proceeds, allotment date, and purpose of the share issuance.
- Confirm the post-issuance total number of ordinary shares and total voting rights.
- Assess potential dilution to existing shareholders and any related financing or corporate-action terms.